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The DYSCERNE Network of Centres of Expertise for
dysmorphology (http://www.dyscerne.org), is developing
clinical management guidelines for Williams (WS),
Angelman (AS), Noonan (NS) and Kabuki (KS) syn-
dromes. An initial scoping exercise identified these con-
ditions as rare, complex, multi-system disorders, for
which it was felt that affected patients, families and
health/social care professionals would benefit from
access to up-to-date evidence based management
guidelines.
Published evidence from which to develop manage-
ment recommendations for these conditions is very lim-
ited, and devising a systematic and robust methodology
has been challenging. Our approach is based on the
Scottish Intercollegiate Guidelines Network (SIGN)
method, which we modified placing more emphasis on
expert opinion and consensus, whilst maintaining sys-
tematic rigour and transparency of processes.
The development process includes:
- Identification of key management issues by guideline
group leaders.
- Targeted, systematic literature searches using
PubMed.
- Review, identification and grading of results by panel
of invited experts.
- Consensus meetings at which experts present, dis-
cuss and agree recommendations.
- Initial drafting of guideline document which is circu-
lated amongst experts and stakeholders for comments.
- Amendments incorporated and guidelines finalised.
- Guidelines piloted and evaluated.
- International dissemination.
The process has involved 49 experts from 8 countries
reviewing between them, over 1000 papers. The WS
guidelines are currently being piloted in 20 centres, by
paediatricians and geneticists. The first draft of AS
guidelines has been circulated for feedback. Consensus
meetings for NS and KS will be held very shortly. The
finished guidelines will be available from the DYS-
CERNE website.
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